SEC Filing Summary

This filing details stock transactions by Peter Blume-Jensen and Kristina Masson, officers and directors of Acrivon Therapeutics, Inc. On February 21, 2026, Peter Blume-Jensen disposed of 14,265 shares of Common Stock at $1.53 per share, leaving him with 2,080,204 shares. This disposal was to cover tax withholdings related to restricted stock units. Additionally, Kristina Masson holds 314,127 shares of Common Stock, which are also subject to spousal disclaimers as noted in the footnotes. Both individuals are executives and directors at the company.